Ocular surface bandage in eyedrop form – safer and more effective use of therapies to restore sight

这种“液体凝胶”眼药水可以在眼睛表面传递并保留治疗药物6-8小时。这种材料在增厚之前从滴管中挤出，作为一种治疗、保护和可吸收的层覆盖在眼睛上，眨眼几个小时就可以清除。该技术解决了传统眼药水快速（1-15分钟）清除的问题，而传统眼药水要保持有效剂量，特别是对于眼睛前部的情况，可能需要非常频繁地给药或使用专家的隐形眼镜，但非常不舒服。非常频繁的给药可能有毒性作用的风险，患者通常难以耐受，并可能降低付款人的成本效益。这些因素威胁着治疗方法的广泛采用。缺乏好的产品来帮助管理长期的眼病，往往意味着健康的人的工作和社交生活受到影响。商业机会在于与制药/生物技术公司合作，将液体凝胶嵌入其药物管道中，从而更有效地利用每种剂量，以最大限度地提高治疗效果。这项技术的独特之处在于，它具有隐形眼镜的保护优势，但与其他眼药水一样容易使用。眼药水的机械特性可以定制，而不会产生复杂的化学变化，使新药能够通过最短的调节途径进入临床。这种液体凝胶是安全的，可以很快以可扩展的方式达到临床级别，并将进入人体试验。整体报价在商业化方面处于独特而及时的地位。

The 'fluid-gel' eyedrop that can deliver and _retain_ incorporated therapeutics on the surface of the eye for 6-8 hours. The material flows upon extrusion from an eyedropper before thickening, as a therapeutic, protective and resorbable layer over the eye, which is cleared away by blinking over several hours. The technology tackles the issue of rapid (1-15 mins) clearance of conventional eyedrops where maintaining effective doses, especially for conditions of the front of the eye, can require very frequent dosing or use with specialist, but very uncomfortable, contact lenses. Very frequent dosing can risk toxicity effects, is generally poorly tolerated by patients, and can diminish the perceived cost-benefit to payors. These factors threaten wide adoption of therapies. Lack of good products to even help _manage_ long-term eye conditions often means the working and social lives of otherwise healthy people are impacted.The commercial opportunity is in partnering with pharma/biotech companies to embed fluid-gel into their drug pipelines, enabling more effective use of each dose to maximise therapeutic effect. The technology is unique in that it has the protective advantage of a contact lens but is as easy to apply as any other eyedrop. The mechanical properties of the eyedrop can be tailored without complex chemical changes, enabling new drug products take the shortest regulatory pathway possible to the clinic. The fluid-gel is safe, can soon be made to clinical grade in a scalable manner and will enter human trials. The overall offer is in a unique and timely position for commercialisation.